We are international
trials TEXT SIZE   

Elotuzumab (formerly known as HuLuc63) is a monoclonal antibody that targets CS1, a cell surface glycoprotein highly expressed on myeloma cells but minimally expressed on normal cells. Elotuzumab is currently in clinical trials for newly diagnosed, previously untreated and relapsed or refractory myeloma.


Expanded Access Treatment Protocol CA204-143
The objective of this expanded access program is to provide treatment with elotuzumab in combination with lenalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma at U.S. sites where licensed physicians determine clinical need.

ClinicalTrials.gov Identifier:

Clinical Trial Fact Sheet for the ELOQUENT - 1 Trial

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma.

The Eloquent Trial fact sheets are also available in German, French, Italian, Spanish, and Dutch.

Clinical Trial Fact Sheet for the ELOQUENT - 2 Trial
Phase III Randomized, Open-label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Relapsed or Refractory Multiple Myeloma

Open Clinical Trials at clinicaltrials.gov